Try our beta test site
394 studies found for:    biogen | biogen
Show Display Options
Rank Status Study
21 Completed Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient
Condition: Healthy
Intervention: Drug: BG00012
22 Available Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)
Condition: Infantile-onset Spinal Muscular Atrophy (SMA)
Intervention: Drug: nusinersen
23 Completed Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: Interferon-beta-1a;   Drug: methylprednisolone
24 Completed A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
Condition: Relapsing Forms of Multiple Sclerosis
Interventions: Procedure: Plasma exchange;   Drug: natalizumab treatment
25 Completed A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis
Condition: Exercise
Intervention:
26 Completed Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers
Condition: Healthy
Interventions: Drug: BIIB014;   Other: [11C]SCH442416
27 Completed Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Drug: BIIB014;   Drug: Placebo
28 Not yet recruiting Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Other: Vitamin K Cream;   Other: Placebo Cream
29 Not yet recruiting Cognitive Change in Behavioral Variant Frontotemporal Dementia (FTD)
Conditions: Frontotemporal Dementia (FTD);   Behavioral Variant Frontotemporal Dementia (bvFTD)
Intervention:
30 Not yet recruiting Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia
Condition: Trigeminal Neuralgia
Interventions: Drug: BIIB074;   Drug: Placebo
31 Not yet recruiting Long-Term Evaluation of BIIB067
Condition: ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
Intervention: Drug: BIIB067
32 Recruiting Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: BIIB076;   Drug: Placebo
33 Not yet recruiting MS PATHS Normative Sub-Study
Condition: Multiple Sclerosis (MS)
Intervention:
34 Recruiting Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
Condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: Daclizumab
35 Recruiting Study to Evaluate BIIB059 in CLE With or Without SLE
Conditions: Systemic Lupus Erythematosus (SLE);   Active Cutaneous Lupus Erythematosus (CLE)
Interventions: Drug: BIIB059;   Drug: Placebo
36 Recruiting Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Condition: Acute Ischemic Stroke
Interventions: Drug: natalizumab;   Drug: Placebo
37 Recruiting Single and Multiple Dose Study of BIIB067 in Adults With Amyotrophic Lateral Sclerosis (ALS)
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: BIIB067;   Other: Placebo
38 Recruiting Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Condition: Amyotrophic Lateral Sclerosis (ALS)
Intervention:
39 Recruiting Plegridy Satisfaction Study in Participants
Condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: peginterferon beta-1a
40 Recruiting Tecfidera and the Gut Microbiota
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: dimethyl fumarate;   Drug: injectable MS DMT

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.